论文部分内容阅读
作者以29例低密度胆固醇水平在180mg/dl以上的早期高胆固醇血症病人为对象,采用安慰剂对照、交叉试验,研究了降血脂药苯扎贝特(bezafibrate)和吉非罗齐(gemfibrozil)对血清脂蛋白水平的影响。受试者参试前预先排除甲状腺、肝、肾病患者,其中15例有冠心病或心肌梗塞症状存在。分别给予受试者苯扎贝特200mg一天3次,或吉非罗齐600mg一天2次,或安慰剂口服,每期8周,共4期。各期期末测定受试者血清胆固醇、甘油三酸酯和阿扑脂蛋白
The aim of this study was to investigate the effects of bezafibrate and gemfibrozil, a lipid-lowering drug, on 29 hypercholesterolemic patients with low LDL cholesterol above 180 mg / dl in a placebo-controlled, crossover trial. ) On serum lipoprotein levels. Subjects pre-excluded before thyroid, liver, kidney disease, of which 15 cases of coronary heart disease or myocardial infarction symptoms exist. Subjects were given bezafibrate 200mg three times a day, or gemfibrozil 600mg twice a day, or placebo orally, each period of 8 weeks, a total of 4. Subjects were tested for serum cholesterol, triglycerides and apolipoproteins at the end of each period